Julius Clinical
Erik van Zandbergen is currently the Chief Operating Officer at Julius Clinical, where he also holds the title of Chief Commercial Officer focusing on bold and creative drug development solutions. Additionally, he is the CEO of ENT Clinical, a company specializing in translational hearing discoveries into treatments for patients. Erik is the Company Owner of AvanZa Health and previously served as the VP Clinical Research at NIZO. With a background in project management and business development in the pharmaceutical industry, Erik has a strong track record of acquiring new clients and managing clinical trials. He holds a MSc in PharmD from the University of Groningen.
Julius Clinical
At Julius Clinical, science is the foundation. Combined with flexibility, creativity, and innovation, our scientific approach enables fast, efficient, and high quality execution of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases. Our partners include leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators. We focus on clinical trials that are likely to have a major impact on medicine and on people’s lives. This type of demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables to deliver results efficiently, on time and budget. Julius Clinical has on its staff internationally recognised academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility, combined with personal links with peers around the world, means that the company has a truly global reach and reputation. Through our global networks we can quickly select the most appropriate and high-performing sites to take part in a trial, and ensure that investigators are inspired and motivated.